炎症性关节病中疼痛的复杂性:超越疼痛强度与影响的OMERACT倡议
OMERACT 2025疼痛特别兴趣小组(SIG)会议汇集24名参与者,探讨炎症性关节炎(IA)中不同疼痛亚型(包括伤害性、神经病理性及伤害可塑性疼痛)的评估难题。通过投票和讨论,多数参与者(86%,19/24)支持首先进行系统综述以寻找或开发伤害可塑性疼痛的标准化测量工具,且仅1/24认为现行IASP定义可直接用于IA。
要点
- IA患者疼痛包括伤害性、神经病理性及伤害可塑性疼痛等不同亚型。
- 86%(19/24)参与者支持先系统综述现有文献以识别验证工具。
- 仅1/24认为现行IASP伤害可塑性疼痛定义可直接适用于IA。
核心结论
- OMERACT 2025疼痛SIG会议形成共识:需推进识别或开发IA伤害可塑性疼痛的结局测量工具,并可能需对现有定义进行情境化调整。
研究设计与样本
- OMERACT 2025疼痛SIG会议,共24名参与者,包括患者、临床医生、研究者、方法学家及行业代表,通过演讲、投票和讨论形成意见。
主要发现
- 投票显示明确同意推进识别或开发伤害可塑性疼痛的结局测量工具。
- 86%(19/24)参与者支持首先进行系统综述以识别合适的验证工具。
- 在疼痛神经科学教育后,6名患者研究伙伴(PRP)中5名(83%)同意能报告IA中经历的不同疼痛类型。
- 仅1/24参与者同意现行IASP伤害可塑性疼痛定义直接适用于IA,96%不同意或不确定,超过半数(14/24)认为该定义可能需要针对IA进行情境化。
关键数值与推荐
- 86%(19/24)参与者支持首先进行系统综述。
- 6名PRP中5名(83%)同意能报告不同疼痛类型。
- 1/24参与者同意现行IASP定义直接适用,96%不同意或不确定,14/24认为需要情境化。
临床怎么用
- 临床中应识别IA患者可能合并伤害可塑性疼痛,尤其对 optimal 治疗后仍持续疼痛者。
- 未来临床试验可考虑采用标准化伤害可塑性疼痛测量工具以优化入组标准及分层策略。
局限性
- 会议样本量小(24人),投票结果基于参与者意见,非大规模临床验证。
- 尚未确定具体的伤害可塑性疼痛测量工具,需进一步系统综述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: People with IA may suffer from pain of differing aetiologies and subtypes including nociceptive joint pain, neuropathic pain of carpal tunnel syndrome or nociplastic pain from concomitant fibromyalgia. Lack of precise measurement tools to identify nociplastic pain influences as a contextual factor potentially all outcomes in collected clinical trials as residual pain might impact various measurements in IA. The OMERACT 2025 pain SIG discussed, developing a scoping review from protocol, to identify an instrument to measure nociplastic pain in IA and a contextualised domain definition for nociplastic pain in IA. Stakeholder opinions were sought regarding pain in IA and the importance of identifying an instrument to measure nociplastic pain in IA. METHODS: A total of twenty-four participants attending the OMERACT 2025 pain SIG session included a mix of patients, clinicians, researchers, methodologists, and industry representatives. Patient research partner (PRP), MC spoke about the impact of pain including different pain subtypes in IA. She recapped the results of OMERACT 2023 poll where participants, including PRPs, agreed that assessing different pain subtypes in IA was important to improve targeted treatments for pain. SK - a pain specialist- presented evidence supporting the presence and impact of nociplastic pain in different IA's including rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondylarthritis (AxSpA). Details of the scoping review protocol developed by the OMERACT Pain Working Group identifying candidate instruments for nociplastic pain assessment in IA was presented. Participants opinions were polled regarding their perspectives of the nociplastic pain definition and measurement. RESULTS: Polling showed clear agreement on advancing efforts to identify or develop an outcome measure for nociplastic pain. Most participants (86 %, 19/24) endorsed beginning with a systematic review of the existing literature to identify an appropriate validated instrument. Following a pain neuroscience education session five of the six (83 %) patient research partners (PRP) agreed they would be able to report the different pain types experienced in IA. Only one participant (1/24) agreed that the current IASP nociplastic pain definition is directly applicable to IA. Most participants (96 %) either disagreed or were uncertain, and over half (14/24) felt the definition likely requires contextualisation for IA. DISCUSSION: There was broad agreement that, in a substantial proportion of patients with inflammatory arthritis, nociplastic pain persists despite optimal treatment, is challenging to manage in routine clinical practice, and is associated with substantial patient suffering. The OMERACT meeting underscored the need for a standardized measure of nociplastic pain in inflammatory arthritis to refine eligibility criteria and support the development of stratified approaches in future clinical trials.
引用
- Khot S, Cowern M, Djurtoft C, et al. The complexity of pain in inflammatory arthropathies beyond pain intensity and impact: An OMERACT initiative. Semin Arthritis Rheum. 2026. PMID: 41856014. doi:10.1016/j.semarthrit.2026.152962
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。